טוען...

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib

BACKGROUND: In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement characterizes a subgroup of patients who show sensitivity to ALK tyrosine kinase inhibitors (TKIs). However, the prognoses of these patients are heterogeneous. A better understanding of the genomic alte...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	Transl Lung Cancer Res
Main Authors:	Li, Jingjing, Zhang, Bin, Zhang, Yu, Xu, Feng, Zhang, Zhenfa, Shao, Lin, Yan, Chunhe, Ulivi, Paola, Denis, Marc G., Christopoulos, Petros, Thomas de Montpréville, Vincent, Bernicker, Eric H., van der Wekken, Anthonie J., Wang, Changli, Yue, Dongsheng
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	AME Publishing Company 2021
נושאים:	Original Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC8044492/ https://ncbi.nlm.nih.gov/pubmed/33889527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-21-160
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib

פריטים דומים